Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -31.49% is 92% above its 5-year average of -388.81%, near the high end of its 5-year range (-1220.05%–50.05%).
47.26% above its 12-month average of -59.71%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 50.05%.
EBITDA MARGIN
-31.49%
EBITDA MARGIN AVG TTM
-59.71%
EBITDA MARGIN AVG 3Y
-491.50%
EBITDA MARGIN AVG 5Y
-388.81%
EBITDA MARGIN AVG 10Y
-397.38%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+47.26%
CURRENT VS 3Y AVG
+93.59%
CURRENT VS 5Y AVG
+91.90%
CURRENT VS 10Y AVG
+92.08%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Liquidia Corporation
Market Cap
$2.36B
EBITDA Margin
-31.49%
TTM Avg
-59.71%
3Y Avg
-491.50%
5Y Avg
-388.81%
Market Cap
$2.37B
EBITDA Margin
-317.71%
TTM Avg
-346.77%
3Y Avg
-338.06%
5Y Avg
-349.04%
Market Cap
$2.39B
EBITDA Margin
39.11%
TTM Avg
36.80%
3Y Avg
16.06%
5Y Avg
-24.25%
Market Cap
$2.40B
EBITDA Margin
-4.36%
TTM Avg
-3.80%
3Y Avg
-12.43%
5Y Avg
-17.77%
Market Cap
$2.31B
EBITDA Margin
26.92%
TTM Avg
28.50%
3Y Avg
31.74%
5Y Avg
29.80%
Market Cap
$2.41B
EBITDA Margin
-37.02%
TTM Avg
-37.02%
3Y Avg
-37.02%
5Y Avg
-37.02%
Market Cap
$2.30B
EBITDA Margin
29.14%
TTM Avg
-19.91%
3Y Avg
8.86%
5Y Avg
26.54%
Market Cap
$2.43B
EBITDA Margin
-755.79%
TTM Avg
-753.93%
3Y Avg
-709.93%
5Y Avg
-1157.85%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Liquidia Corporation (LQDA) | $2.36B | -31.49% | -59.71% | -491.50% | -388.81% |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.37B | -317.71% | -346.77% | -338.06% | -349.04% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.39B | 39.11% | 36.80% | 16.06% | -24.25% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.40B | -4.36% | -3.80% | -12.43% | -17.77% |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.31B | 26.92% | 28.50% | 31.74% | 29.80% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.41B | -37.02% | -37.02% | -37.02% | -37.02% |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.30B | 29.14% | -19.91% | 8.86% | 26.54% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.43B | -755.79% | -753.93% | -709.93% | -1157.85% |
| Disc Medicine, Inc. (IRON)vs › | $2.46B | N/A | N/A | N/A | N/A |
| Pharvaris N.V. (PHVS)vs › | $2.15B | N/A | N/A | N/A | N/A |
Gross Margin
92.5%
EBITDA Margin
-31.5%
Operating Margin
-32.5%
Net Margin
30.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 50.05% |
| 2026-03-31 | 46.66% |
| 2025-12-31 | 21.85% |
| 2025-09-30 | 4.13% |
| 2025-06-30 | -421.23% |
| 2025-03-31 | -1120.96% |
| 2024-12-31 | -1220.05% |
| 2024-09-30 | -642.51% |
| 2024-06-30 | -727.44% |
| 2024-03-31 | -952.62% |
| 2023-12-31 | -574.22% |
| 2023-09-30 | -388.50% |
| 2023-06-30 | -464.61% |
| 2023-03-31 | -192.81% |
| 2022-12-31 | -110.65% |
| 2022-09-30 | -243.38% |
| 2022-06-30 | -203.27% |
| 2022-03-31 | -383.79% |
| 2021-12-31 | -326.31% |
| 2021-09-30 | -174.11% |
| 2021-06-30 | -141.23% |
| 2021-03-31 | -239.69% |
| 2020-12-31 | -2022.96% |
| 2019-06-30 | -64.71% |
| 2018-12-31 | -1645.18% |
| 2018-09-30 | -5220.77% |
| 2018-06-30 | -628.96% |
| 2018-03-31 | -923.64% |
| 2017-12-31 | -381.43% |
| 2017-09-30 | -415.74% |
| 2017-06-30 | -305.49% |
| 2017-03-31 | -399.25% |
